n multidistrict litigations, bellwether trials are intended to function as test cases, and the outcome of this case may provide valuable insight into jury rulings in similar Lipitor lawsuits.
New York, New York (PRWEB) March 31, 2015
Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/ ) filed on behalf of individuals who allegedly developed new-onset Type 2 diabetes due to the use of the cholesterol-lowering medication continue to move forward in the federal multidistrict litigation now underway in U.S. District Court, District of South Carolina. According to an Order issued on March 26th, jury selection for the proceeding’s first bellwether trial will begin on November 4, 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is currently representing clients in this litigation, and we look forward to the start of this trial. In multidistrict litigations, bellwether trials are intended to function as test cases, and the outcome of this case may provide valuable insight into jury rulings in similar Lipitor lawsuits,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to provide free and confidential case reviews to individuals who may have been harmed by Lipitor.
Court records indicate that more than 2,000 cases are now pending in the federal litigation underway in South Carolina. The Lipitor lawsuit selected for the proceeding’s first bellwether trial was filed on behalf of a woman who began taking the drug in 1998, and was diagnosed with Type 2 diabetes in 2004. Like other plaintiffs who have filed claims in this litigation, she alleges that Pfizer knew or should have known about the link between Lipitor and diabetes for years, yet withheld information from consumers and the medical community. (Case No. 2:2015cv01132)
According to court documents, the Lipitor litigation began to grow after the U.S. Food & Drug Administration (FDA) issued an alert in February 2012 warning that cholesterol-lowering statins like Lipitor might be associated with an increased risk of new-onset Type 2 diabetes. At the time, the agency disclosed that it would require that new information be added to the labels of Lipitor and other statins regarding their potential effect on blood glucose levels. However, Lipitor lawsuit plaintiffs claim that the label modifications made by Pfizer in response to the FDA’s mandate are still not sufficient.
Individuals who allegedly developed Type 2 diabetes due to their use of Lipitor may be eligible to pursue their own lawsuit against Pfizer. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have ben able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com